Hero image with Pittsburgh background pittplusme.org/study/1277

STUDY BASICS

Have you been diagnosed with hormone receptor positive or triple negative breast cancer that is growing on your chest wall (chest wall disease)? If so, you may be eligible to participate in a study to help researchers see what effects, good or bad, the combination of pembrolizumab (KEYTRUDA) and carboplatin (chemotherapy) have on your cancer compared to carboplatin alone.


IRB:
  STUDY19110231 - A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Age Range
AGE:   18 and up

Location LOCATION: 
Magee-Women’s Hospital of UPMC
Compensation COMPENSATION: 

NONE

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1277
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet